November 30, 2012
Bookmark and Share  



This month we have several new and important items for you at the HCV and HBV Websites:


This eblast has information about the first interferon-free phase III data of GS-7977 plus ribavirin to treat HCV genotype 2, and 3 with an SVR of 78%.  Treatment duration was 12 weeks.  This is a milestone moment in the history of and treatment for HCV—following in the footsteps of this combination are more DAA combinations without interferon in mid-stage development

Gilead hepatitis C drug shows promise in late-stage trial


1. December 2012 HCV Advocate

In This Issue:

  • AASLD 2012 Part 1: HCV Therapies
    Alan Franciscus, Editor-in-Chief: In Part 1 of AASLD conference coverage I concentrate on the DAA combination therapies without interferon—some of which did not even include ribavirin!

  • HCV Snapshots: AASLD 2012
    Lucinda K. Porter, RN: Lucinda's conference coverage includes many interesting presentations such as drug-drug interactions with boceprevir and telaprevir, confusion with acetaminophen labeling, and an interesting study on the differences in response rates between men and women and much, much more.

  • HealthWise: - 2012 Liver Meeting Update
    Lucinda K. Porter, RN
    : This month's "HealthWise" features commentary about AASLD and some thoughts about giving to HCV organizations.

  • Disability & Benefits:Are There Benefits to a Reverse Mortgage?
    Jacques Chambers, CLU
    : Reverse mortgages have been in the news lately there are lots of pitfalls for people unless they are carefu. Jacques writes about the pros and cons, and in a word be careful.

2. HBV Journal Review by Christine Kukka —In this month's column Chris reviews the following studies. Hepatitis B is a complicated disease to understand and manage. Christine's monthly review provides much needed information to stay up to date and live healthy with hepatitis B :

  • Vaccination May Not Protect Against HBV with Surface Antigen Mutation

  • HBV-Infected Fathers Appear Not to Pose Infection Risk to Fetuses

  • Genotype B Prone to Chronic Infection, and Genotype D Prone to Liver Cancer Despite Treatment

  • Lamivudine Results Raising Concern Among Researchers

  • HBeAg Seroconversion Rate Lower with Entecavir Than Earlier Reported

  • Environmental Toxin Dramatically Increases Liver Cancer in Asia and Africa

  • Antivirals Reduce Liver Cancer Risk in Some–But Not All

  • Because It Can Be Reversed, New Terminology Needed to Describe Cirrhosis

  • Depression During Interferon More Severe in Hepatitis C Than Hepatitis B Patients

  • Nearly Half of HBV-Infected Children Eventually Lose HBeAg–With or Without Treatment

  • Researchers Identify the Protein Doorway That Allows HBV to Infect Liver Cells

  • Tenofovir Used to Treat Many Newly-Infected with Multi-Drug Resistant HBV

  • Another Study Links Hepatitis B and Diabetes

3. HCV Drug Pipelinehas been updated to include the most recent news items. 




U.S. Preventive Services Task Force

The U.S. Preventive Services Task Force makes recommendations for testing for certain conditions and diseases. Their recommendations can affect whether a physician will order a test or even alert their patients that there may be a disease that they could or should be tested for.

Please read the draft statement carefully. There is a link on the right-hand side of the page that will take you to a webpage that will allow you to make comments.

Please let U.S. Preventive Services know what you think about their recommendations whether you agree or disagree with their recommendations or if you think the language and recommendations should be stronger. It could make a difference in how USPSTF recommends testing for HCV.

5. Training ScheduleDon’t forget to keep checking our Upcoming Training Workshop Schedules to see if we will be in your neighborhood soon!



Don’t forget that there is help as close as a phone call – the 877-HELP-4-HEP line (877-435-7443) is available 9:00am to 7:00pm Eastern Time.  For more information about the services they offer either call or visit their Website at  The helpline is run by The Support Partnership:  a group of non-profits working together to help people affected by hepatitis C. 


7. Top News (Blog) from the hepatitis blog includes: 

AASLD 2012

Liver Cancer Spikes Among Spanish Coinfected With HIV, Hepatitis
November 27

Sexual transmission of HCV among monogamous heterosexual couples: The HCV partners study
November 27

Zinc supplement helps hepatitis C
November 27

Less Support for Hepatitis C Testing for Baby Boomers
November 27

Gilead hepatitis C drug shows promise in late-stage trial
November 27

Sharing drug preparation equipment a potential source of hepatitis C transmission
November 27

Gilead Announces Sustained Virologic Response Rate of 78% from Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients
November 27

Grapefruit Drug Interactions: Fruit Reacts Dangerously With Expanding List Of Medications, Study Says
November 26

Doctors should consider hepatitis C testing: panel
November 26

Devon Nicholson Hep C treatment Chronicles – Week 4 – "Blood Work and Virus Tests"
November 26

Mom, daughter won't let hepatitis C define them
November 25

Update: Local Veterinarian cured of Hepatitis C
November 22

National Summit on HIV and Viral Hepatitis Convenes November 26-28 in Washington With Focus on Accelerating HIV/Hepatitis C Testing and Reducing Disparities in Care
November 21

Triple Therapy Boosts HCV Response After Transplant
November 20

Simeprevir is safe and effective with interferon/ribavirin for hepatitis C patients with cirrhosis
November 19

Nail salons should be regulated to help prevent the spread of infections: report
November 19

Researcher hunts for hepatitis C cure
November 19

Ontario doctors question long wait for hepatitis C drug Incivek
November 19

FDA approves new indication for PROMACTA® (eltrombopag)
November 19



 and much, much more…..




Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate
Editor-in-Chief, HBV Advocate

**Questions and Comments: Questions and/or comments can be directed to

**To receive the eblast in your email inbox simply send an e-mail to: with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.